首页> 外文OA文献 >Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

【2h】

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

机译：晚期NSCLC顺铂-吉西他滨诱导化疗后吉西他滨或厄洛替尼维持治疗联合预定义二线治疗的成本效益分析：IFCT-GFPC 0502-Eco III期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Isabelle Borget; Maurice Pérol; David Pérol; Armelle Lavolé; Laurent Greillier; Pascal Dô; Virginie Westeel; Jacky Crequit; Hervé Léna; Isabelle Monnet; Hervé Le Caer; Pierre Fournel; Lionel Falchero; Michel Poudenx; Fabien Vaylet; Sylvie Chabaud; Alain Vergnenegre; Gérard Zalcman; Christos Chouaïd;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study [J] . Isabelle Borget, Maurice Pérol, David Pérol, BMC Cancer . 2014,第1期

机译：吉西他滨或厄洛替尼维持疗法与顺铂-吉西他滨诱导化疗后晚期NSCLC的预定义二线治疗观察的费用效用分析：IFCT-GFPC 0502-Eco III期研究
2. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation,with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer [J] . PérolM., ChouaidC., PérolD., Journal of Clinical Oncology . 2012,第28期

机译：吉西他滨或厄洛替尼维持治疗与观察与随机二线治疗的随机，III期研究在晚期非小细胞肺癌顺铂-吉西他滨诱导化疗后的应用
3. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study [J] . BylickiO., FerlayC., ChouaidC., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2013,第7期

机译：在IFCT-GFPC 05-02的III期研究中，培美曲塞作为晚期NSCLC的二线治疗在无治疗间隔或吉西他滨或厄洛替尼维持治疗后的疗效
4. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
5. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study [O] . Isabelle Borget, Maurice Pérol, David Pérol, 2014

机译：吉西他滨或厄洛替尼维持疗法与顺铂-吉西他滨诱导化疗后晚期NSCLC的预定义二线治疗观察相比的成本-效用分析：IFCT-GFPC 0502-Eco III期研究
6. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study [O] . Borget Isabelle, Pérol Maurice, Pérol David, 2014

机译：吉西他滨或厄洛替尼维持治疗与顺铂-吉西他滨诱导化疗后晚期NSCLC的预定义二线治疗观察的费用效用分析：IFCT-GFPC 0502-Eco III期研究

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

著录项

相似文献

相关主题

期刊订阅